Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn

AIMS: Metabolic syndrome (MetSyn) is associated with high risk of cardiovascular (CV) events, irrespective of statin therapy. In the overall REDUCE-IT study of statin-treated patients, icosapent ethyl (IPE) reduced the risk of the primary composite endpoint (CV death, non-fatal myocardial infarction...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Michael, Bhatt, Deepak L, Brinton, Eliot A, Jacobson, Terry A, Steg, Philippe Gabriel, Pineda, Armando Lira, Ketchum, Steven B, Doyle, Ralph T, Tardif, Jean-Claude, Ballantyne, Christie M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684296/
https://www.ncbi.nlm.nih.gov/pubmed/38035037
http://dx.doi.org/10.1093/ehjopen/oead114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684296/
https://www.ncbi.nlm.nih.gov/pubmed/38035037
http://dx.doi.org/10.1093/ehjopen/oead114

Ejemplares similares